Alphaeon Inc. 11.24.15
Alphaeon Corporation is purchasing Lensar Inc. for $59 million in cash, stock and assumed debt. The deal is expected to close by Dec. 31.
Lensar is a global developer and manufacturer of femtosecond laser systems (through a wholly-owned subsidiary). Its Lensar Laser System is designed for patients seeking a premium vision outcome following the removal of their crystalline lens. With this announcement, Alphaeon expands its global ophthalmology business, and enables the company to provide advanced technology to its network of more than 2,000 board-certified ophthlmologists globally.
"Lensar has advanced the self-pay category of precision refractive surgery both for ophthalmologists as well as their patients," said Robert E. Grant, Alphaeon CEO. "The addition of Lensar to our lifestyle product portfolio will provide ophthalmologists with another alternative to expand their offering to patients. We are very pleased at the opportunity to welcome Lensar employees to our team."
"The opportunity to partner with Alphaeon furthers Lensar's commitment to provide ophthalmologists everywhere with the latest developments in premium vision surgery," said Nick Curtis, Lensar CEO. "We're excited about the chance to join Alphaeon, and together leverage our proprietary platform technology to develop new clinical innovations benefiting physicians and patients alike."
Lensar is a commercial stage medical device firm providing femtosecond laser technology for cataract treatment. Founded in 2004 and based in Orland, Fla., Lensar developed the first femtosecond cataract laser to enable automation of several critical surgical procedure planning and delivering elements.
Alphaeon describes itself as a social commerce company focused on transforming self-pay healthcare by bringing to market innovative products and services to promote consumer wellness, beauty and performance. The Irvine, Calif.-based company works in partnership with board-certified physicians ensuring access to leading advancements in lifestyle healthcare.
Lensar is a global developer and manufacturer of femtosecond laser systems (through a wholly-owned subsidiary). Its Lensar Laser System is designed for patients seeking a premium vision outcome following the removal of their crystalline lens. With this announcement, Alphaeon expands its global ophthalmology business, and enables the company to provide advanced technology to its network of more than 2,000 board-certified ophthlmologists globally.
"Lensar has advanced the self-pay category of precision refractive surgery both for ophthalmologists as well as their patients," said Robert E. Grant, Alphaeon CEO. "The addition of Lensar to our lifestyle product portfolio will provide ophthalmologists with another alternative to expand their offering to patients. We are very pleased at the opportunity to welcome Lensar employees to our team."
"The opportunity to partner with Alphaeon furthers Lensar's commitment to provide ophthalmologists everywhere with the latest developments in premium vision surgery," said Nick Curtis, Lensar CEO. "We're excited about the chance to join Alphaeon, and together leverage our proprietary platform technology to develop new clinical innovations benefiting physicians and patients alike."
Lensar is a commercial stage medical device firm providing femtosecond laser technology for cataract treatment. Founded in 2004 and based in Orland, Fla., Lensar developed the first femtosecond cataract laser to enable automation of several critical surgical procedure planning and delivering elements.
Alphaeon describes itself as a social commerce company focused on transforming self-pay healthcare by bringing to market innovative products and services to promote consumer wellness, beauty and performance. The Irvine, Calif.-based company works in partnership with board-certified physicians ensuring access to leading advancements in lifestyle healthcare.